Portfolio Holdings Detail for ISIN IE00B3VWM098
Stock Name / Fund iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer Blackrock
Entity holding fund iShares VII Public Limited Company
Entity Type Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300Q7FFITMZ2PFZ28
ETF Ticker CUS1(GBX) LSE
ETF Ticker CUSS(USD) LSE
ETF Ticker SXRG(EUR) F
ETF Ticker CSUSS.MI(EUR) CXE
ETF Ticker CSUSSz(USD) CXE
ETF Ticker CUSS.LS(USD) CXE
ETF Ticker CSUSS(EUR) ETF Plus
ETF Ticker CUS1.L(GBP) LSE
ETF Ticker CUSS.L(GBP) LSE

Holdings detail for AGIO

Stock Name	Agios Pharm
Ticker	AGIO(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US00847X1046
LEI	529900ONJHY8EOGYT555

Show aggregate AGIO holdings

News associated with AGIO

AGIO Crosses Below Key Moving Average Level: In trading on Thursday, shares of Agios Pharmaceuticals Inc (Symbol: AGIO) crossed below their 200 day moving average of $35.78, changing hands as low as $32.70 per share. Agios Pharmaceuticals Inc shares are currently trading down about 14.2% on the day. The chart below shows - 2025-09-04 12:41:27
Deutsche Bank AG Lowers Stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO): Deutsche Bank AG decreased its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report) by 0.7% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 928,970 shares of the biopharmaceutical company’s stock after selling 6,282 shares during the quarter. Deutsche Bank AG’s […] - 2025-08-13 05:20:52
Monday's ETF Movers: SPXL, BBSC: In trading on Monday, the Direxion Daily S&P 500 Bull 3X ETF is outperforming other ETFs, up about 3.5% on the day. Components of that ETF showing particular strength include shares of Idexx Laboratories, up about 26.2% and shares of Martin Marietta Materials, up about 5.1% - 2025-08-04 13:04:13
Agios Pharmaceuticals Becomes Oversold (AGIO): Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me - 2025-08-04 12:58:40
Agios Pharmaceuticals (AGIO) Shares Cross Below 200 DMA: In trading on Thursday, shares of Agios Pharmaceuticals Inc (Symbol: AGIO) crossed below their 200 day moving average of $36.97, changing hands as low as $35.81 per share. Agios Pharmaceuticals Inc shares are currently trading down about 0.6% on the day. The chart below shows - 2025-07-31 14:21:35
Bullish Two Hundred Day Moving Average Cross - AGIO: In trading on Wednesday, shares of Agios Pharmaceuticals Inc (Symbol: AGIO) crossed above their 200 day moving average of $37.36, changing hands as high as $38.82 per share. Agios Pharmaceuticals Inc shares are currently trading up about 6.6% on the day. The chart below shows - 2025-07-09 12:42:52
Analysts Set Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Price Target at $58.60: Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Get Free Report) have been assigned an average rating of “Moderate Buy” from the seven research firms that are presently covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month […] - 2025-07-02 03:14:49
Agios' PYRUKYND Faces FDA Review In September - Expansion Opportunity Ahead?: (RTTNews) - Shares of Agios Pharmaceuticals Inc. (AGIO) have retreated approximately 43% from their 52-week high of $62.58, reported last November, and trade near the $35 level. - 2025-06-17 08:36:03
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 9,606 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO): UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report) by 8.5% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 122,835 shares of the biopharmaceutical company’s stock after acquiring an additional 9,606 shares during […] - 2025-06-05 05:13:00
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Given Average Rating of “Moderate Buy” by Brokerages: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Get Free Report) has earned an average recommendation of “Moderate Buy” from the eight research firms that are presently covering the firm, MarketBeat reports. Three investment analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1-year target price […] - 2025-06-04 04:52:50
Two Sigma Advisers LP Takes Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO): Two Sigma Advisers LP acquired a new stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 22,200 shares of the biopharmaceutical company’s stock, valued at approximately $729,000. A number of other […] - 2025-06-03 04:56:54
Two Sigma Investments LP Makes New $3.59 Million Investment in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO): Two Sigma Investments LP purchased a new position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report) in the fourth quarter, HoldingsChannel.com reports. The firm purchased 109,373 shares of the biopharmaceutical company’s stock, valued at approximately $3,594,000. A number of other hedge funds and other institutional investors have also bought and sold shares of AGIO. Jefferies […] - 2025-05-30 05:24:59
BNP Paribas Financial Markets Lowers Stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO): BNP Paribas Financial Markets decreased its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report) by 18.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,704 shares of the biopharmaceutical company’s stock after selling 2,242 shares during the quarter. BNP Paribas Financial […] - 2025-05-27 04:38:56
Agios Pharmaceuticals (NASDAQ:AGIO) Rating Lowered to Sell at StockNews.com: StockNews.com downgraded shares of Agios Pharmaceuticals (NASDAQ:AGIO – Free Report) from a hold rating to a sell rating in a research report released on Monday morning. Several other brokerages also recently commented on AGIO. Scotiabank reduced their target price on Agios Pharmaceuticals from $74.00 to $71.00 and set a “sector outperform” rating for the company […] - 2025-05-20 02:36:56
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Stock Position Reduced by Voya Investment Management LLC: Voya Investment Management LLC cut its holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report) by 48.2% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 33,007 shares of the biopharmaceutical company’s stock after selling 30,733 shares during the period. Voya Investment Management LLC’s holdings in Agios Pharmaceuticals were worth $1,085,000 as of its […] - 2025-05-07 06:32:51
Scotiabank Cuts Agios Pharmaceuticals (NASDAQ:AGIO) Price Target to $71.00: Agios Pharmaceuticals (NASDAQ:AGIO – Free Report) had its price objective lowered by Scotiabank from $74.00 to $71.00 in a research note published on Friday morning,Benzinga reports. The firm currently has a sector outperform rating on the biopharmaceutical company’s stock. A number of other equities analysts also recently commented on AGIO. HC Wainwright assumed coverage on […] - 2025-05-05 04:38:49
CANADA LIFE ASSURANCE Co Sells 1,094 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO): CANADA LIFE ASSURANCE Co reduced its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report) by 5.5% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 18,979 shares of the biopharmaceutical company’s stock after selling 1,094 shares during the period. CANADA LIFE ASSURANCE […] - 2025-04-30 05:48:58
Invesco Ltd. Sells 35,432 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO): Invesco Ltd. reduced its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report) by 29.8% in the fourth quarter, HoldingsChannel reports. The firm owned 83,515 shares of the biopharmaceutical company’s stock after selling 35,432 shares during the quarter. Invesco Ltd.’s holdings in Agios Pharmaceuticals were worth $2,744,000 as of its most recent filing […] - 2025-04-29 04:25:06
Barclays PLC Sells 90,864 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO): Barclays PLC lowered its stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report) by 42.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 121,753 shares of the biopharmaceutical company’s stock after selling 90,864 shares during the quarter. Barclays PLC owned approximately 0.21% […] - 2025-04-28 05:01:17
Legal & General Group Plc Sells 1,424 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO): Legal & General Group Plc lessened its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report) by 1.9% in the fourth quarter, HoldingsChannel.com reports. The firm owned 71,677 shares of the biopharmaceutical company’s stock after selling 1,424 shares during the quarter. Legal & General Group Plc’s holdings in Agios Pharmaceuticals were worth $2,355,000 […] - 2025-04-25 05:08:57
Federated Hermes Inc. Purchases 582 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO): Federated Hermes Inc. lifted its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report) by 4.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 13,691 shares of the biopharmaceutical company’s stock after buying an additional 582 shares during the period. Federated […] - 2025-04-18 04:53:04
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives $56.57 Consensus PT from Analysts: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the nine research firms that are covering the stock, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 12 month […] - 2025-04-18 02:28:57
Norges Bank Takes $4.77 Million Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO): Norges Bank purchased a new stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report) during the 4th quarter, HoldingsChannel.com reports. The institutional investor purchased 145,092 shares of the biopharmaceutical company’s stock, valued at approximately $4,768,000. Several other hedge funds and other institutional investors also recently added to or reduced their stakes in AGIO. NEOS Investment […] - 2025-04-10 05:02:57
Vanguard Group Inc. Grows Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO): Vanguard Group Inc. raised its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report) by 1.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,631,321 shares of the biopharmaceutical company’s stock after buying an additional 85,339 shares during the […] - 2025-04-07 05:06:53
Thrivent Financial for Lutherans Sells 7,077 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO): Thrivent Financial for Lutherans decreased its holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report) by 28.8% in the fourth quarter, HoldingsChannel.com reports. The fund owned 17,526 shares of the biopharmaceutical company’s stock after selling 7,077 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Agios Pharmaceuticals were worth $576,000 at the end of […] - 2025-04-04 04:32:55
Brokerages Set Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) PT at $56.57: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the nine brokerages that are currently covering the company, Marketbeat.com reports. Four research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average twelve-month price target […] - 2025-03-26 04:57:01
Short Interest in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Decreases By 14.9%: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Get Free Report) was the target of a significant drop in short interest during the month of February. As of February 28th, there was short interest totalling 3,940,000 shares, a drop of 14.9% from the February 13th total of 4,630,000 shares. Based on an average daily volume of 895,400 shares, […] - 2025-03-21 04:26:52
AlphaQuest LLC Increases Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO): AlphaQuest LLC raised its stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report) by 106.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,540 shares of the biopharmaceutical company’s stock after buying an additional 2,338 shares during the quarter. AlphaQuest […] - 2025-03-18 06:03:33
New York State Common Retirement Fund Purchases 4,663 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO): New York State Common Retirement Fund boosted its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report) by 13.5% in the fourth quarter, Holdings Channel reports. The fund owned 39,093 shares of the biopharmaceutical company’s stock after purchasing an additional 4,663 shares during the quarter. New York State Common Retirement Fund’s holdings in […] - 2025-03-03 07:20:48
Agios Pharmaceuticals (NASDAQ:AGIO) Cut to Sell at StockNews.com: StockNews.com lowered shares of Agios Pharmaceuticals (NASDAQ:AGIO – Free Report) from a hold rating to a sell rating in a research note issued to investors on Friday morning. A number of other research firms have also recently commented on AGIO. Cantor Fitzgerald restated an “overweight” rating on shares of Agios Pharmaceuticals in a research report […] - 2025-02-17 04:53:15

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc AGIO holdings

Date	Number of AGIO Shares Held	Base Market Value of AGIO Shares	Local Market Value of AGIO Shares	Change in AGIO Shares Held	Change in AGIO Base Value	Current Price per AGIO Share Held	Previous Price per AGIO Share Held
2025-12-11 (Thursday)	21,558	USD 591,983	USD 591,983	0	USD -11,641	USD 27.46	USD 28
2025-12-10 (Wednesday)	21,558	USD 603,624	USD 603,624	0	USD 24,792	USD 28	USD 26.85
2025-12-09 (Tuesday)	21,558	USD 578,832	USD 578,832	0	USD -9,270	USD 26.85	USD 27.28
2025-12-08 (Monday)	21,558	USD 588,102	USD 588,102	0	USD -9,701	USD 27.28	USD 27.73
2025-12-05 (Friday)	21,558	USD 597,803	USD 597,803	0	USD 6,683	USD 27.73	USD 27.42
2025-12-04 (Thursday)	21,558	USD 591,120	USD 591,120	0	USD -1,509	USD 27.42	USD 27.49
2025-12-03 (Wednesday)	21,558	USD 592,629	USD 592,629	-380	USD 742	USD 27.49	USD 26.98
2025-12-02 (Tuesday)	21,938	USD 591,887	USD 591,887	152	USD -14,635	USD 26.98	USD 27.84
2025-12-01 (Monday)	21,786	USD 606,522	USD 606,522	0	USD -29,629	USD 27.84	USD 29.2
2025-11-28 (Friday)	21,786	USD 636,151	USD 636,151	0	USD 3,486	USD 29.2	USD 29.04
2025-11-27 (Thursday)	21,786	USD 632,665	USD 632,665	0	USD 0	USD 29.04	USD 29.04
2025-11-26 (Wednesday)	21,786	USD 632,665	USD 632,665	0	USD 13,398	USD 29.04	USD 28.425

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of AGIO by Blackrock for IE00B3VWM098

Show aggregate share trades of AGIO

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-12-03 SELL -380 27.720 27.000 27.072 USD -10,287 36.81 Profit of 3,701 on sale
2025-12-02 BUY 152 27.990 26.810 26.928 USD 4,093 36.86
2025-11-25 SELL -228 28.630 26.360 26.587 USD -6,062 37.06 Profit of 2,387 on sale
2025-11-24 BUY 16,343 26.750 24.960 25.139 USD 410,847 37.11
2025-11-17 SELL -209 45.960 42.500 42.846 USD -8,955 37.22 Loss of -1,175 on sale
2025-11-12 SELL -19 44.550 43.200 43.335 USD -823 37.13 Loss of -118 on sale
2025-11-06 SELL -19 40.860 39.940 40.032 USD -761 37.04 Loss of -57 on sale
2025-11-05 SELL -190 40.720 39.210 39.361 USD -7,479 37.02 Loss of -445 on sale
2025-11-04 SELL -38 40.320 38.900 39.042 USD -1,484 37.00 Loss of -77 on sale
2025-11-03 SELL -38 44.100 39.960 40.374 USD -1,534 36.99 Loss of -129 on sale
2025-10-28 BUY 57 43.430 43.780 43.745 USD 2,493 36.86
2025-10-24 SELL -19 43.330 43.430 43.420 USD -825 36.79 Loss of -126 on sale
2025-10-15 BUY 114 41.380 41.710 41.677 USD 4,751 36.58
2025-10-02 BUY 19 39.930 40.580 40.515 USD 770 36.53
2025-09-30 BUY 38 40.140 40.200 40.194 USD 1,527 36.49
2025-08-21 SELL -19 38.200 38.460 38.434 USD -730 36.45 Loss of -38 on sale
2025-07-31 BUY 57 37.220 37.940 37.868 USD 2,158 36.44
2025-06-30 SELL -38 33.260 33.890 33.827 USD -1,285 36.26 Profit of 92 on sale
2025-06-25 SELL -19 32.710 33.730 33.628 USD -639 36.32 Profit of 51 on sale
2025-06-20 SELL -38 34.410 35.880 35.733 USD -1,358 36.38 Profit of 24 on sale
2025-05-23 BUY 19 29.800 29.870 29.863 USD 567 36.89
2025-05-19 SELL -19 29.840 29.990 29.975 USD -570 37.13 Profit of 136 on sale
2025-05-15 SELL -57 28.260 28.460 28.440 USD -1,621 37.28 Profit of 504 on sale
2025-05-12 SELL -19 29.140 29.390 29.365 USD -558 37.51 Profit of 155 on sale
2025-05-09 SELL -19 27.320 28.910 28.751 USD -546 37.61 Profit of 168 on sale
2025-04-30 SELL -19 29.690 30.060 30.023 USD -570 38.17 Profit of 155 on sale
2025-04-24 SELL -38 29.260 29.300 29.296 USD -1,113 38.53 Profit of 351 on sale
2025-04-17 SELL -19 27.660 28.380 28.308 USD -538 39.10 Profit of 205 on sale
2025-04-15 SELL -57 27.820 28.240 28.198 USD -1,607 39.35 Profit of 636 on sale
2025-04-14 SELL -57 27.520 27.710 27.691 USD -1,578 39.48 Profit of 672 on sale
2025-04-09 SELL -76 26.280 27.080 27.000 USD -2,052 39.94 Profit of 983 on sale
2025-04-07 SELL -133 25.900 27.090 26.971 USD -3,587 40.28 Profit of 1,770 on sale
2025-04-04 SELL -190 25.760 27.860 27.650 USD -5,254 40.45 Profit of 2,432 on sale
2025-03-31 BUY 19 29.300 29.830 29.777 USD 566 40.89
2025-03-19 SELL -38 31.680 31.740 31.734 USD -1,206 41.93 Profit of 387 on sale
2025-03-14 SELL -114 30.930 31.850 31.758 USD -3,620 42.37 Profit of 1,210 on sale
2025-03-13 SELL -38 31.070 32.500 32.357 USD -1,230 42.54 Profit of 387 on sale
2025-03-12 SELL -646 31.980 33.070 32.961 USD -21,293 42.69 Profit of 6,284 on sale
2025-03-07 SELL -38 32.380 34.470 34.261 USD -1,302 43.17 Profit of 338 on sale
2025-03-06 SELL -57 33.980 34.330 34.295 USD -1,955 43.31 Profit of 514 on sale
2025-03-03 SELL -19 33.120 35.700 35.442 USD -673 43.78 Profit of 158 on sale
2025-02-28 SELL -114 35.540 35.540 35.540 USD -4,052 43.92 Profit of 955 on sale
2025-02-26 SELL -19 34.440 36.070 35.907 USD -682 44.24 Profit of 158 on sale
2025-02-25 SELL -57 35.190 35.750 35.694 USD -2,035 44.40 Profit of 496 on sale
2025-02-18 BUY 95 33.610 34.860 34.735 USD 3,300 45.34
2025-02-13 BUY 19 33.300 33.490 33.471 USD 636 46.07
2025-02-12 BUY 19 32.810 33.340 33.287 USD 632 46.34
2025-02-11 BUY 57 32.660 33.810 33.695 USD 1,921 46.62
2025-02-06 BUY 171 34.420 34.940 34.888 USD 5,966 47.47
2025-01-27 BUY 19 33.750 35.250 35.100 USD 667 50.38
2024-12-30 BUY 95 33.030 33.800 33.723 USD 3,204 52.40
2024-12-06 BUY 76 61.640 62.450 62.369 USD 4,740 52.43
2024-12-05 BUY 19 58.970 60.930 60.734 USD 1,154 52.21
2024-12-04 BUY 95 59.450 62.150 61.880 USD 5,879 51.95
2024-11-29 BUY 95 59.390 59.860 59.813 USD 5,682 51.10
2024-11-27 BUY 76 58.660 59.620 59.524 USD 4,524 50.44
2024-11-26 BUY 19 59.100 59.610 59.559 USD 1,132 50.04
2024-11-25 SELL -5,263 57.510 58.250 58.176 USD -306,180 49.69 Loss of -44,667 on sale
2024-11-21 BUY 175 55.540 56.270 56.197 USD 9,834 49.07
2024-11-20 BUY 105 54.620 55.300 55.232 USD 5,799 48.76
2024-11-18 BUY 420 52.890 54.000 53.889 USD 22,633 48.15
2024-11-12 BUY 280 59.020 60.300 60.172 USD 16,848 47.42
2024-11-08 BUY 175 59.060 60.210 60.095 USD 10,517 46.59
2024-11-07 BUY 525 55.080 55.190 55.179 USD 28,969 45.94
2024-11-06 BUY 70 51.590 51.640 51.635 USD 3,614 45.47
2024-10-31 BUY 35 44.430 45.900 45.753 USD 1,601 45.59
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-12-03	SELL	-380	27.720	27.000	27.072	USD -10,287	36.81 Profit of 3,701 on sale
2025-12-02	BUY	152	27.990	26.810	26.928	USD 4,093	36.86
2025-11-25	SELL	-228	28.630	26.360	26.587	USD -6,062	37.06 Profit of 2,387 on sale
2025-11-24	BUY	16,343	26.750	24.960	25.139	USD 410,847	37.11
2025-11-17	SELL	-209	45.960	42.500	42.846	USD -8,955	37.22 Loss of -1,175 on sale
2025-11-12	SELL	-19	44.550	43.200	43.335	USD -823	37.13 Loss of -118 on sale
2025-11-06	SELL	-19	40.860	39.940	40.032	USD -761	37.04 Loss of -57 on sale
2025-11-05	SELL	-190	40.720	39.210	39.361	USD -7,479	37.02 Loss of -445 on sale
2025-11-04	SELL	-38	40.320	38.900	39.042	USD -1,484	37.00 Loss of -77 on sale
2025-11-03	SELL	-38	44.100	39.960	40.374	USD -1,534	36.99 Loss of -129 on sale
2025-10-28	BUY	57	43.430	43.780	43.745	USD 2,493	36.86
2025-10-24	SELL	-19	43.330	43.430	43.420	USD -825	36.79 Loss of -126 on sale
2025-10-15	BUY	114	41.380	41.710	41.677	USD 4,751	36.58
2025-10-02	BUY	19	39.930	40.580	40.515	USD 770	36.53
2025-09-30	BUY	38	40.140	40.200	40.194	USD 1,527	36.49
2025-08-21	SELL	-19	38.200	38.460	38.434	USD -730	36.45 Loss of -38 on sale
2025-07-31	BUY	57	37.220	37.940	37.868	USD 2,158	36.44
2025-06-30	SELL	-38	33.260	33.890	33.827	USD -1,285	36.26 Profit of 92 on sale
2025-06-25	SELL	-19	32.710	33.730	33.628	USD -639	36.32 Profit of 51 on sale
2025-06-20	SELL	-38	34.410	35.880	35.733	USD -1,358	36.38 Profit of 24 on sale
2025-05-23	BUY	19	29.800	29.870	29.863	USD 567	36.89
2025-05-19	SELL	-19	29.840	29.990	29.975	USD -570	37.13 Profit of 136 on sale
2025-05-15	SELL	-57	28.260	28.460	28.440	USD -1,621	37.28 Profit of 504 on sale
2025-05-12	SELL	-19	29.140	29.390	29.365	USD -558	37.51 Profit of 155 on sale
2025-05-09	SELL	-19	27.320	28.910	28.751	USD -546	37.61 Profit of 168 on sale
2025-04-30	SELL	-19	29.690	30.060	30.023	USD -570	38.17 Profit of 155 on sale
2025-04-24	SELL	-38	29.260	29.300	29.296	USD -1,113	38.53 Profit of 351 on sale
2025-04-17	SELL	-19	27.660	28.380	28.308	USD -538	39.10 Profit of 205 on sale
2025-04-15	SELL	-57	27.820	28.240	28.198	USD -1,607	39.35 Profit of 636 on sale
2025-04-14	SELL	-57	27.520	27.710	27.691	USD -1,578	39.48 Profit of 672 on sale
2025-04-09	SELL	-76	26.280	27.080	27.000	USD -2,052	39.94 Profit of 983 on sale
2025-04-07	SELL	-133	25.900	27.090	26.971	USD -3,587	40.28 Profit of 1,770 on sale
2025-04-04	SELL	-190	25.760	27.860	27.650	USD -5,254	40.45 Profit of 2,432 on sale
2025-03-31	BUY	19	29.300	29.830	29.777	USD 566	40.89
2025-03-19	SELL	-38	31.680	31.740	31.734	USD -1,206	41.93 Profit of 387 on sale
2025-03-14	SELL	-114	30.930	31.850	31.758	USD -3,620	42.37 Profit of 1,210 on sale
2025-03-13	SELL	-38	31.070	32.500	32.357	USD -1,230	42.54 Profit of 387 on sale
2025-03-12	SELL	-646	31.980	33.070	32.961	USD -21,293	42.69 Profit of 6,284 on sale
2025-03-07	SELL	-38	32.380	34.470	34.261	USD -1,302	43.17 Profit of 338 on sale
2025-03-06	SELL	-57	33.980	34.330	34.295	USD -1,955	43.31 Profit of 514 on sale
2025-03-03	SELL	-19	33.120	35.700	35.442	USD -673	43.78 Profit of 158 on sale
2025-02-28	SELL	-114	35.540	35.540	35.540	USD -4,052	43.92 Profit of 955 on sale
2025-02-26	SELL	-19	34.440	36.070	35.907	USD -682	44.24 Profit of 158 on sale
2025-02-25	SELL	-57	35.190	35.750	35.694	USD -2,035	44.40 Profit of 496 on sale
2025-02-18	BUY	95	33.610	34.860	34.735	USD 3,300	45.34
2025-02-13	BUY	19	33.300	33.490	33.471	USD 636	46.07
2025-02-12	BUY	19	32.810	33.340	33.287	USD 632	46.34
2025-02-11	BUY	57	32.660	33.810	33.695	USD 1,921	46.62
2025-02-06	BUY	171	34.420	34.940	34.888	USD 5,966	47.47
2025-01-27	BUY	19	33.750	35.250	35.100	USD 667	50.38
2024-12-30	BUY	95	33.030	33.800	33.723	USD 3,204	52.40
2024-12-06	BUY	76	61.640	62.450	62.369	USD 4,740	52.43
2024-12-05	BUY	19	58.970	60.930	60.734	USD 1,154	52.21
2024-12-04	BUY	95	59.450	62.150	61.880	USD 5,879	51.95
2024-11-29	BUY	95	59.390	59.860	59.813	USD 5,682	51.10
2024-11-27	BUY	76	58.660	59.620	59.524	USD 4,524	50.44
2024-11-26	BUY	19	59.100	59.610	59.559	USD 1,132	50.04
2024-11-25	SELL	-5,263	57.510	58.250	58.176	USD -306,180	49.69 Loss of -44,667 on sale
2024-11-21	BUY	175	55.540	56.270	56.197	USD 9,834	49.07
2024-11-20	BUY	105	54.620	55.300	55.232	USD 5,799	48.76
2024-11-18	BUY	420	52.890	54.000	53.889	USD 22,633	48.15
2024-11-12	BUY	280	59.020	60.300	60.172	USD 16,848	47.42
2024-11-08	BUY	175	59.060	60.210	60.095	USD 10,517	46.59
2024-11-07	BUY	525	55.080	55.190	55.179	USD 28,969	45.94
2024-11-06	BUY	70	51.590	51.640	51.635	USD 3,614	45.47
2024-10-31	BUY	35	44.430	45.900	45.753	USD 1,601	45.59

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of AGIO

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	66,908	0	122,346	54.7%
2025-09-18	107,747	0	245,827	43.8%
2025-09-17	120,521	6	236,006	51.1%
2025-09-16	96,865	7	184,380	52.5%
2025-09-15	118,459	10	164,576	72.0%
2025-09-12	70,299	0	216,181	32.5%
2025-09-11	59,764	0	205,227	29.1%
2025-09-10	86,293	0	254,457	33.9%
2025-09-09	134,717	0	222,059	60.7%
2025-09-08	152,472	1,048	281,198	54.2%
2025-09-05	402,261	2,719	568,902	70.7%
2025-09-04	724,185	13,979	1,196,899	60.5%
2025-09-03	183,410	12,130	258,807	70.9%
2025-09-02	148,082	600	204,223	72.5%
2025-08-29	73,826	100	138,702	53.2%
2025-08-28	84,013	0	148,016	56.8%
2025-08-27	205,307	0	325,310	63.1%
2025-08-26	81,476	0	172,165	47.3%
2025-08-25	106,699	0	271,700	39.3%
2025-08-22	158,363	460	219,936	72.0%
2025-08-21	171,667	900	192,102	89.4%
2025-08-20	70,628	0	91,838	76.9%
2025-08-19	215,285	0	258,851	83.2%
2025-08-18	193,961	0	235,195	82.5%
2025-08-15	79,832	0	110,711	72.1%
2025-08-14	57,294	0	82,325	69.6%
2025-08-13	112,768	0	172,693	65.3%
2025-08-12	95,468	0	145,367	65.7%
2025-08-11	132,797	0	211,978	62.6%
2025-08-08	92,144	3,366	174,430	52.8%
2025-08-07	136,944	158	178,218	76.8%
2025-08-06	262,113	118	362,072	72.4%
2025-08-05	252,723	4,006	386,830	65.3%
2025-08-04	1,234,835	19,021	2,629,492	47.0%
2025-08-01	976,822	3,396	1,054,061	92.7%
2025-07-31	367,020	0	527,359	69.6%
2025-07-30	304,028	0	365,506	83.2%
2025-07-29	157,934	1	221,901	71.2%
2025-07-28	151,657	0	237,953	63.7%
2025-07-25	139,643	22	240,961	58.0%
2025-07-24	88,686	106	205,180	43.2%
2025-07-23	209,448	2	440,983	47.5%
2025-07-22	137,870	0	376,995	36.6%
2025-07-21	96,551	0	204,504	47.2%
2025-07-18	153,114	60	261,825	58.5%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.

Stock Name / Fund	iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer	Blackrock
Entity holding fund	iShares VII Public Limited Company
Entity Type	Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI	549300Q7FFITMZ2PFZ28
ETF Ticker	CUS1(GBX) LSE
ETF Ticker	CUSS(USD) LSE
ETF Ticker	SXRG(EUR) F
ETF Ticker	CSUSS.MI(EUR) CXE
ETF Ticker	CSUSSz(USD) CXE
ETF Ticker	CUSS.LS(USD) CXE
ETF Ticker	CSUSS(EUR) ETF Plus
ETF Ticker	CUS1.L(GBP) LSE
ETF Ticker	CUSS.L(GBP) LSE